Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jan Berger
AddedFeb 15, 2024
UpdatedMay 31, 2026
Jan Berger

Jan Berger

Board Member, Cambia Health Solutions

CrunchbaseLinkedInThe Org

Jan Berger's Career

Cambia Health Solutions
Cambia Health Solutions

Portland, OR, US

Board Member· Board
UCB
UCB

City of Brussels, Flemish Brabant, BE

Board Member· Board
Aitia
Aitia

Somerville, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jan Berger's Career

Cambia Health Solutions
Cambia Health Solutions
Investment FirmInvestment Firm4.4k1996Portland, OR, US
Board Member· Board

Leadership at Cambia Health Solutions

Jared ShortJared ShortCEO
Luis MachucaLuis MachucaBoard Member
Mark GanzMark GanzBoard Member
Kent IvanoffKent IvanoffBoard Member
Susannah FoxSusannah FoxBoard Member
Michael KoppelMichael KoppelBoard Member
UCB
UCB
Public$195.3M7.6k1928City of Brussels, Flemish Brabant, BE
Board Member· Board

Recent news

Castelion is raising a $350M Series B to scale hypersonic missile businessTechCrunch · 2025

Leadership at UCB

Jonathan PeacockJonathan PeacockBoard Member
Jean-Christophe TellierJean-Christophe TellierBoard Member
Gerhard MayrGerhard MayrBoard Member
Stefan OschmannStefan OschmannBoard Member
Charles-Antoine JanssenCharles-Antoine JanssenBoard Member
Ulf WiinbergUlf WiinbergBoard Member

Similar to UCB

Bristol Myers SquibbBristol Myers SquibbNew York City, NY, USPharmaceuticalsest. 1887Bristol Myers SquibbNew York City, NY, US · est. 1887

Leading American pharmaceutical company specializing in research and development.

Public · $10.6B34.3k
JanssenJanssenBeerse, Antwerp, BEPharmaceuticalsest. 1953JanssenBeerse, Antwerp, BE · est. 1953

Janssen, a Johnson & Johnson company in Italy, innovates to manage, interpret, and prevent diseases, ensuring affordable, effective healthcare worldwide.

Public255
AstraZenecaAstraZenecaCambridge, Cambridgeshire, GBPharmaceuticalsest. 1999AstraZenecaCambridge, Cambridgeshire, GB · est. 1999

AstraZeneca PLC: A British-Swedish firm specializing in research, manufacturing, and sales of pharmaceuticals.

Public · $3.8B83.5k
SanofiSanofiParis, Paris, FRPharmaceuticalsest. 1973SanofiParis, Paris, FR · est. 1973

Sanofi, a global French pharmaceutical firm, manufactures prescription drugs and vaccines, specializing in various medical fields.

Public · $610M91.6k
Aitia
Aitia
Series D$77.3M882000Somerville, MA, US
Board Member· Board

Leadership at Aitia

Colin HillColin HillCo-Founder
Iya KhalilIya KhalilCo-Founder
Rob CoppedgeRob CoppedgeBoard Member
Colin HillColin HillCEO
Siraj MohammedSiraj MohammedCo-Founder

Similar to Aitia

ConcertAIConcertAICambridge, MA, USData Analytics, Medical Researchest. 2018ConcertAICambridge, MA, US · est. 2018

ConcertAI: Leveraging AI and real-world data for innovative oncology research and care solutions.

Series C · $300M
Pathos AIPathos AIChicago, IL, USDrug Discoveryest. 2020Pathos AIChicago, IL, US · est. 2020

Pathos: AI and big data-driven platform streamlining end-to-end drug discovery and development.

Series B · $20M3
InsitroInsitroSouth San Francisco, CA, USDrug Discoveryest. 2018InsitroSouth San Francisco, CA, US · est. 2018

Insitro: Leveraging machine learning for data-driven drug discovery and development.

Series C · $643M295
BioAI HealthBioAI HealthGoffstown, NH, USAI Diagnostics, Biotechest. 2020BioAI HealthGoffstown, NH, US · est. 2020

BioAI Health: Leveraging AI for improved disease diagnosis, therapy response prediction, and clinical trials.

Seed · $3M9

Jan Berger's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakChi-hyung SongChi-hyung SongBoard Member · DunamuWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailJaeHong ChoiJaeHong ChoiBoard Member · KakaoMason YeoMason YeoBoard Member · Kakao

People Similar to Jan Berger

Swati AbbottSwati AbbottBoard Member · Prognos HealthJay AckermanJay AckermanCo-Founder & CEO · AttaTeam!Scott JensScott JensBoard Member · ThirdSpaceSloan SaundersSloan SaundersFounder · Cedar Hill HoldingsEran PeeryEran PeeryBoard Member · Double Check SolutionsJerry BragerJerry BragerBoard Member · 1-800-Doctors